Peptor, Xoma deal

XOMA and Peptor (Rehovot, Israel) will develop anti-fungal peptides derived from XOMA’s bactericidal/permeability increasing protein (rBPI) product. Peptor will apply its cyclizing technology to XOMA’s lead anti-fungal candidates to create cyclized peptides with increased potency and stability. The process will involve chemically restructuring candidate molecules by linking atoms in the peptides’ structural backbones. ...